DE69525631T2 - Verwendung von prostaglandinen zur herstellung eines arzneimittels zur prävention und behandlung des sekundären katarakts - Google Patents
Verwendung von prostaglandinen zur herstellung eines arzneimittels zur prävention und behandlung des sekundären kataraktsInfo
- Publication number
- DE69525631T2 DE69525631T2 DE69525631T DE69525631T DE69525631T2 DE 69525631 T2 DE69525631 T2 DE 69525631T2 DE 69525631 T DE69525631 T DE 69525631T DE 69525631 T DE69525631 T DE 69525631T DE 69525631 T2 DE69525631 T2 DE 69525631T2
- Authority
- DE
- Germany
- Prior art keywords
- prostaglandin
- pct
- prostaglandines
- treating
- preventing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000008516 Capsule Opacification Diseases 0.000 title abstract 2
- 208000002177 Cataract Diseases 0.000 title abstract 2
- 229940126601 medicinal product Drugs 0.000 title 1
- 150000003180 prostaglandins Chemical class 0.000 abstract 3
- BGKHCLZFGPIKKU-UHFFFAOYSA-N (13E,15S)-15-hydroxy-9-oxo-prosta-10,13-dienoic acid Natural products CCCCCC(O)C=CC1C=CC(=O)C1CCCCCCC(O)=O BGKHCLZFGPIKKU-UHFFFAOYSA-N 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Prostheses (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9403160A SE9403160D0 (sv) | 1994-09-21 | 1994-09-21 | Method and means for prevention and treatment of secondary cataract |
| PCT/SE1995/001058 WO1996009054A1 (en) | 1994-09-21 | 1995-09-19 | Method and means for prevention and treatment of secondary cataract |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69525631D1 DE69525631D1 (de) | 2002-04-04 |
| DE69525631T2 true DE69525631T2 (de) | 2002-07-18 |
Family
ID=20395311
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69525631T Expired - Fee Related DE69525631T2 (de) | 1994-09-21 | 1995-09-19 | Verwendung von prostaglandinen zur herstellung eines arzneimittels zur prävention und behandlung des sekundären katarakts |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US5760075A (de) |
| EP (1) | EP0782447B1 (de) |
| JP (1) | JPH10505860A (de) |
| AT (1) | ATE213634T1 (de) |
| AU (1) | AU704459B2 (de) |
| CA (1) | CA2200481C (de) |
| DE (1) | DE69525631T2 (de) |
| ES (1) | ES2170807T3 (de) |
| SE (1) | SE9403160D0 (de) |
| WO (1) | WO1996009054A1 (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999005278A1 (en) * | 1997-07-23 | 1999-02-04 | Brigham & Women's Hospital, Inc. | Lens epithelial cell derived growth factor |
| US6750052B1 (en) | 1997-07-23 | 2004-06-15 | The Brigham And Women's Hospital, Inc. | Lens epithelial cell derived growth factor |
| US6533769B2 (en) * | 2001-05-03 | 2003-03-18 | Holmen Joergen | Method for use in cataract surgery |
| US20080038316A1 (en) * | 2004-10-01 | 2008-02-14 | Wong Vernon G | Conveniently implantable sustained release drug compositions |
| US9993558B2 (en) | 2004-10-01 | 2018-06-12 | Ramscor, Inc. | Sustained release eye drop formulations |
| US8541413B2 (en) * | 2004-10-01 | 2013-09-24 | Ramscor, Inc. | Sustained release eye drop formulations |
| MX344532B (es) * | 2004-10-01 | 2016-12-19 | Ramscor Inc | Composiciones de farmaco de liberacion sostenida convenientemente implantables. |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58216155A (ja) * | 1982-06-10 | 1983-12-15 | Ono Pharmaceut Co Ltd | 新規なプロスタグランジンｄ類似化合物 |
| ES2053458T3 (es) * | 1986-03-13 | 1994-08-01 | Univ Columbia | Utilizacion de prostaglandinas a, b y c y derivados de las mismas, para el tratamiento de la hipertension ocular y glaucoma. |
| TW224942B (de) * | 1990-04-04 | 1994-06-11 | Adka Ueno Kk |
-
1994
- 1994-09-21 SE SE9403160A patent/SE9403160D0/xx unknown
-
1995
- 1995-09-19 EP EP95932999A patent/EP0782447B1/de not_active Expired - Lifetime
- 1995-09-19 ES ES95932999T patent/ES2170807T3/es not_active Expired - Lifetime
- 1995-09-19 AT AT95932999T patent/ATE213634T1/de not_active IP Right Cessation
- 1995-09-19 DE DE69525631T patent/DE69525631T2/de not_active Expired - Fee Related
- 1995-09-19 US US08/809,343 patent/US5760075A/en not_active Expired - Fee Related
- 1995-09-19 JP JP8510805A patent/JPH10505860A/ja active Pending
- 1995-09-19 AU AU35816/95A patent/AU704459B2/en not_active Ceased
- 1995-09-19 CA CA002200481A patent/CA2200481C/en not_active Expired - Fee Related
- 1995-09-19 WO PCT/SE1995/001058 patent/WO1996009054A1/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| CA2200481C (en) | 2002-09-10 |
| ATE213634T1 (de) | 2002-03-15 |
| DE69525631D1 (de) | 2002-04-04 |
| SE9403160D0 (sv) | 1994-09-21 |
| EP0782447B1 (de) | 2002-02-27 |
| WO1996009054A1 (en) | 1996-03-28 |
| AU3581695A (en) | 1996-04-09 |
| AU704459B2 (en) | 1999-04-22 |
| EP0782447A1 (de) | 1997-07-09 |
| JPH10505860A (ja) | 1998-06-09 |
| ES2170807T3 (es) | 2002-08-16 |
| US5760075A (en) | 1998-06-02 |
| CA2200481A1 (en) | 1996-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69526937D1 (de) | Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen | |
| DE1300150T1 (de) | Prostaglandin-Derivate zur Behandlung von Glaukom oder Augenüberdruck | |
| ATE164067T1 (de) | Verwendung von riluzole zur behandlung von traumatischen neurologischen-schädigungen | |
| DE69634414D1 (de) | Verwendung von substituierten isochinolinsulfonyl-verbindungen zur herstellung eines medikaments für die behandlung von glaukom und okularer ischämie | |
| DE69616376D1 (de) | Verwendung von Tiagabin zur Behandlung von Schlafstörungen | |
| DE69521620D1 (de) | Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom | |
| DE59409832D1 (de) | Pflaster zur behandlung von nagelmykosen | |
| ATE309795T1 (de) | Acetylcholinesteraseinhibitoren zur behandlung und diagnose von atemstörungen während des schlafes | |
| ATE144420T1 (de) | Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen | |
| ATE217197T1 (de) | Verwendung von hyaluronsäure und eines nsaid zur herstellung eines arzneimittels zur behandlung von krankheiten der mucosa | |
| EA200300560A1 (ru) | Улучшенный способ лечения | |
| ATE179888T1 (de) | Ophthalmische zubereitung zur behandlung oder prävention von trockenem auge und krankheiten, die dadurch verursacht werden, enthaltend 12- sulfodehydroabietsäure | |
| ATE252897T1 (de) | Verwendung von p-aminophenolderivaten zur herstellung von pharmazeutischen zusammensetzungen zur behandlung von neurodegenerativen erkrankungen | |
| ATE307203T1 (de) | Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma | |
| DE69534620D1 (de) | Verfahren zur behandlung von augenerkrankungen | |
| DE69525631T2 (de) | Verwendung von prostaglandinen zur herstellung eines arzneimittels zur prävention und behandlung des sekundären katarakts | |
| DE69516110D1 (de) | Verwendung von riluzol zur behandlung mitochondrialer erkrankungen | |
| DE69424415D1 (de) | Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung parkinsonscher krankheit | |
| DE69421705D1 (de) | Verwendung von Efaroxan und dessen Derivaten zur Herstellung eines Arzneimittels zur Behandlung neurogenerativer Erkrankungen | |
| ATE320263T1 (de) | Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie | |
| DE3585312D1 (de) | Anwendung von 1,6-dimethyl-4-oxo-1,6,7,8,9a-hexahydro-4h-pyrido(1,2-a)pyrimidin-3-carboxamid zur vorbeugung und behandlung von gastrointestinalschaeden. | |
| DE69832796D1 (de) | Verwendung von mizolastine zur herstellung eines arzneimittels zur behandlung von entzündungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8339 | Ceased/non-payment of the annual fee |